About CMA Microdialysis

Guiding therapy for life!

From basic research to clinical routine, Microdialysis is an indispensible tool for discovering, monitoring and guiding therapeutic decisions. CMA’s solutions are used across the globe by drug developers, researchers and caregivers to guide the maze of life. CMA’s dedication and mission is clear, it’s all about guiding therapy for life!

Following our 25th anniversary, we’ve evolved our corporate image and logotype. Our new logo reflects our strong position and our vision “Guiding therapy for life” is our lodestar in whatever we do, produce and deliver.

Company overview

CMA Microdialysis (“CMA”) is a Swedish medical device and research company founded in 1984 as a spin-off from the Karolinska Institute. Unique and market leading solutions are developed, produced and sold to clinicians and researchers to enable optimized patient care and accelerated drug development. CMA’s complete line of instruments, consumables and computer software are used globally by universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and monitoring of organs and blood.

The core competence lies within solutions based on the Microdialysis technique. The products are produced in Sweden under ISO 13485 and according to FDA standards. With a highly specialized and skilled staff, consumables are manufactured in a Class 8 clean room environment. CMA also offers OEM manufacturing services.

The head office is located outside Stockholm, Sweden, with a subsidiary north of Boston, USA. CMA has distributors across the globe, responsible for local sales, service and support.

Highlights & milestones

Ownership and Governance

CMA is primarily owned by Bure AB and Investor Growth Capital, both leading Swedish industrial holding companies listed on the Stockholm Stock Exchange. Mr. Philip Siberg is the CEO and Mr. Thomas Axelsson is the Chairman of the Board. 

History

The concept of Microdialysis was born in the early 1970's. While examining the cross-section of a blood vessel among fluorescent nerve endings, Professor Urban Ungerstedt of the Karolinska Institute in Stockholm had the idea of using a dialysis tube as "an artificial blood capillary", in order to monitor chemical events in the tissue, see Microdialysis technique.

The first paper on Microdialysis was published in 1974. Since then, approximately 13.000 scientific papers have been published on the technique - among them some 2.000 clinical investigations.

Corporate structure

CMA is structured into three market driven business units; Medical, Microdialysis and Discovery. 

The Medical business unit is responsible for marketing Cardiac and Continuous Glucose Monitoring solutions. The product portfolio is based on the new Eirus platform and access devices for continuous monitoring in blood.
Head of the unit is Mr. Måns Alfvén. 

The Microdialysis business unit is responsible for marketing tissue monitoring solutions for neuro and reconstructive surgery. The unit also offers clinical research solutions for many other applications such as Gastrointestinal, Hepatic, Muscle and Skin. Product portfolio is mainly based on the ISCUS platform and a broad range of tissue catheters.
Head of the unit is Miss. Johanna Malm.

The Discovery business unit is responsible for marketing basic research solutions. The unit offers a leading and broad portfolio of Microdialysis products for preclinical use, as well as Automated Blood Sampling products through DiLab.
Head of the unit is Mr. Erik Düring.

The business units are supported by the CMA factory consisting of quality systems, a leading R&D team, Operations (sourcing, production, ordering and shipping), Administration and other corporate functions

Some words from the CEO

With over 25 years of market leadership and excellence, CMA remains unique in offering complete Microdialysis solutions for clinical and research use. With customers in over 60 countries our policy is to develop and produce products that satisfy the highest customer and quality demands. We set the industry standards!

CMA's core competence lies in tissue and blood chemistry and our extensive R&D efforts strive to continuously develop new products and solutions that contribute to a higher quality of life. CMA has tight collaborations with leading research institutes and clinics, which is a prerequisite for successful product development and launch.

Following many years of intense research, I'm now excited to see that Microdialysis is breaking through as a diagnostic tool in clinical care. Our mission continues to be the leading provider of superior tools for metabolic research and diagnostics that offer clear benefits to patients and the healthcare industry.

If you have any ideas or comments, please don't hesitate to contact me.

Philip Siberg
CEO
philip.siberg@microdialysis.se

 For a 6-minute overview of CMA Microdialysis and the opportunities with Clinical Microdialysis, click here